So Zair, what do you think that were the discussion points of the debate?

Well, we had a very fine debate.

between the two highly distinguished opponents.

And as you said, the question raised whether biologics should be introduced early in the therapeutic strategy for lupus, which is a main issue for the lupus management.

As you say, Marie Legato argued that biologics should no longer automatically be reserved until after conventional immunosuppressants fail.

She emphasized that early treatment might mean introducing targeted therapy before conventional immunosuppression, before measurable damage occurs, or within the early years of the disease.

Earlier targeted therapy may accelerate remission and renal response, reduce flares and glucocorticoid exposure, She also presented observational and postdoc evidence suggesting that early belimumab-based strategies may improve outcomes while acknowledging questions of cost and access.

Zahir, do you have comments?